A Look Inside Geron

If you like to see how the sausage is made, Seeking Alpha takes a look inside Geron, a company representative of the messy business of developing the latest regenerative medicine and cancer therapies: "Geron has two telomerase-based cancer drugs in human trials, though both are early stage. For metastatic prostate cancer, the company is injecting telomerase into patients, hoping to provoke a more aggressive immune response - a therapeutic vaccine. ... On the stem cell front, Geron is testing GRNOPC1 to treat spinal cord injuries. The drug was given to rats with injuries that prevented them from using their legs, and GRNOPC1 helped them regain control of their legs. ... A second drug, GRNIC1, uses embryonic stem cell-derived islet clusters treatment to treat diabetes. ... Geron plans to begin its initial human testing of the drug in 2007 ... GRNCM1, the third stem cell based drug candidate, is a potential treatment for myocardial infarction."

Link: http://biotech.seekingalpha.com/article/23090


Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.